Cargando…

CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI

Chronic Myeloid Leukemia (CML) is sustained by a small population of cells with stem cell characteristics known as Leukemic Stem Cells that are positive to BCR-ABL fusion protein, involved with several abnormalities in cell proliferation, expansion, apoptosis and cell cycle regulation. Current treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moreno-Lorenzana, Dafne, Avilés-Vazquez, Sócrates, Sandoval Esquivel, Miguel Angel, Alvarado-Moreno, Antonio, Ortiz-Navarrete, Vianney, Torres-Martínez, Héctor, Ayala-Sánchez, Manuel, Mayani, Héctor, Chavez-Gonzalez, Antonieta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2016
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4889309/ https://www.ncbi.nlm.nih.gov/pubmed/26985855 http://dx.doi.org/10.1080/15384101.2016.1160976

Ejemplares similares

Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species
por: Flores‐Lopez, Gabriela, et al.
Publicado: (2018)

Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib
por: Avilés‐Vázquez, Sócrates, et al.
Publicado: (2017)

The Role of CDKs and CDKIs in Murine Development
por: Campbell, Grace Jean, et al.
Publicado: (2020)

Cell Contact with Endothelial Cells Favors the In Vitro Maintenance of Human Chronic Myeloid Leukemia Stem and Progenitor Cells
por: Torres-Barrera, Patricia, et al.
Publicado: (2022)

Growth effect of tki treatment in childhood CML
por: Jeon, Yeon Jin, et al.
Publicado: (2015)

Dorsal-Ventral Differences in Neural Stem Cell Quiescence Are Induced by p57(KIP2)/Dacapo
por: Otsuki, Leo, et al.
Publicado: (2019)

Effect of Cellular Quiescence on the Success of Targeted CML Therapy
por: Komarova, Natalia L., et al.
Publicado: (2007)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

P653: CML LONG-TERM LEUKEMIC STEM CELL PERSISTENCE IS INFLUENCED BY MYELOFIBROSIS AT DIAGNOSIS
por: Jacobi, Henrike, et al.
Publicado: (2023)

Drug Therapy in the Progressed CML Patient with multi-TKI Failure
por: Haznedaroglu, Ibrahim C.
Publicado: (2015)

P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
por: Semerad, Lukas, et al.
Publicado: (2023)

Regulation of p27(Kip1) and p57(Kip2) Functions by Natural Polyphenols
por: Russo, Gian Luigi, et al.
Publicado: (2020)

Linalool Induces Cell Cycle Arrest and Apoptosis in Leukemia Cells and Cervical Cancer Cells through CDKIs
por: Chang, Mei-Yin, et al.
Publicado: (2015)

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
por: Ramdial, Jeremy L., et al.
Publicado: (2019)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
por: Muselli, Fabien, et al.
Publicado: (2021)

The negative cell cycle regulators, p27(Kip1), p18(Ink4c), and GSK-3, play critical role in maintaining quiescence of adult human pancreatic β-cells and restrict their ability to proliferate
por: Stein, Jeffrey, et al.
Publicado: (2013)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

Acute vision loss due to CML leukemic retinopathy reversed with leukapheresis
por: Leong, Sally, et al.
Publicado: (2023)

Recreating the Bone Marrow Microenvironment to Model Leukemic Stem Cell Quiescence
por: O’Reilly, Eimear, et al.
Publicado: (2021)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
por: Matsushita, Maiko, et al.
Publicado: (2015)

Resveratrol protects leukemic cells against cytotoxicity induced by proteasome inhibitors via induction of FOXO1 and p27(Kip1)
por: Niu, Xiao-Fang, et al.
Publicado: (2011)

Reduced levels of p15INK4b, p16INK4a, p21cip1 and p27kip1 in pancreatic carcinoma
por: LI, GANG, et al.
Publicado: (2012)

Adding a new facet to STAT5 in CML: Multitasking for leukemic cells
por: Warsch, Wolfgang, et al.
Publicado: (2013)

Variable Behavior of iPSCs Derived from CML Patients for Response to TKI and Hematopoietic Differentiation
por: Bedel, Aurélie, et al.
Publicado: (2013)

Delayed Diagnosis and Multi-TKI Intolerance: A Case Report of CML Concurrent With COVID-19
por: Luan, Chengxin, et al.
Publicado: (2022)

p27(Kip1) and Ser10-phosphorylated p27(Kip1) in breast cancer: clinical significance and expression
por: Song, Wei, et al.
Publicado: (2015)

Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML
por: Toda, Jun, et al.
Publicado: (2020)

Loss of quiescence and self-renewal capacity of hematopoietic stem cell in an in vitro leukemic niche
por: Vanegas, Natalia-Del Pilar, et al.
Publicado: (2017)

Immunohistochemical Expression of p27(Kip1), p57(Kip2), Cyclin D1, Nestin, and Ki-67 in Ependymoma
por: Iqneibi, Shahad, et al.
Publicado: (2022)

Re-balance of memory T cell subsets in peripheral blood from patients with CML after TKI treatment
por: Yao, Danlin, et al.
Publicado: (2017)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML
por: Valent, Peter, et al.
Publicado: (2017)

Evaluation of CML TKI Induced Cardiovascular Toxicity and Development of Potential Rescue Strategies in a Zebrafish Model
por: Cheng, Shan, et al.
Publicado: (2021)

Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance
por: Herrmann, Andreas B., et al.
Publicado: (2020)

p27(Kip1) – p(RhoB)lematic in lung cancer
por: Podmirseg, Silvio R, et al.
Publicado: (2019)

p27(kip1): a target for tumor therapies?
por: Nickeleit, Irina, et al.
Publicado: (2007)

p27(Kip1) regulates alpha-synuclein expression
por: Gallastegui, Edurne, et al.
Publicado: (2018)

Role of p27(Kip1) as a transcriptional regulator
por: Bachs, Oriol, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_deuoroeiv4ulhk4c5vprvk9h07